APA citiranje

Murphy, F., Church, D., Medley, L., Davies, J., Breen, D., Clelland, C., . . . Talbot, D. (2011). PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR.

Chicago Style (17th ed.) Citation

Murphy, F., et al. PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR. 2011.

MLA citiranje

Murphy, F., et al. PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR. 2011.